Low extracellular Ca2+: A mediator of endothelial inflammation

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3306-3312

  Talmor Barkan, Yeela ^a,b   Rashid, Gloria ^a   Weintal, Iris ^a   Green, Janice ^a   Bernheim, Jacques ^a,b   Benchetrit, Sydney ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Calcium; Endothelial cells; NF B

Indexed keywords

CALCIUM; CELL PROTEIN; CITRULLINE; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; I KAPPA B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; OSTEOPROTEGERIN; RAGE PROTEIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN RECEPTOR; NOS3 PROTEIN, HUMAN;

ARTICLE; COLORIMETRY; CONTROLLED STUDY; DNA BINDING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR CALCIUM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NEPHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN; BIOSYNTHESIS; CELL CULTURE; GENETICS; INFLAMMATION; METABOLISM; PHYSIOLOGY;

CALCIUM; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE III; OSTEOPROTEGERIN; RECEPTORS, IMMUNOLOGIC; RNA, MESSENGER;

EID: 73949152554     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp354     Document Type: Article

References (58)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
2. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
3. Lopez-Jaramillo P. Calcium, nitric oxide, and preeclampsia. Semin Perinatol 2000; 24: 33-36
4. 2+ concentrations in the production of endothelial nitric oxide and the control of vascular tone. Br J Pharmacol 1990; 101: 489-493
5. Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16: 386-393
6. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43
7. Chan CT, Li SH, Verma S. Nocturnal hemodialysis is associated with restorationofimpaired endothelial progenitor cell biologyinend-stage renal disease. Am J Physiol Renal Physiol 2005; 289: F679-F684
8. Cozzolino M, Galassi A, Pasho S, et al. Preventive measures and new pharmacological approaches of calcium and phosphate disorders. Contrib Nephrol 2008; 161: 234-239
9. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580
10. Ziegelstein RC, Xiong Y, He C, Hu Q. Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 2006; 342: 153-163
11. Weston AH, Absi M, Ward DT, et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells: studies with calindol and Calhex 231. Circ Res 2005; 97: 391-398
12. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-2224
13. Rashid G, Benchetrit S, Fishman D, et al. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int 2004; 66: 1099-1106
14. Shah V, Wiest R, Garcia-Cardena G, et al. Hsp90 regulation of en-dothelial nitric oxide synthase contributes to vascular control in portal hypertension. Am J Physiol 1999; 277: G463-G468
15. Brown EM. The calcium-sensing receptor: physiology, pathophysi-ology and CaR-based therapeutics. Subcell Biochem 2007; 45: 139-167
16. Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol 2008; 3: 1555-1560
17. Locatelli F, Bommer J, London GM, et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol Dial Transplant 2001; 16: 459-468
18. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97
19. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754-759
20. Rashid G, Bernheim J, Green J, et al. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 2007; 292: F1215-F1218
21. Rashid G, Bernheim J, Green J, et al. Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein ki-nase A and C pathways. Nephrol Dial Transplant 2007; 22: 2831-2837
22. Li YC, Kong J, Wei M, et al. 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238
23. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-456
24. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125
25. Talmor Y, Bernheim J, Klein O, et al. Calcitriol blunts pro-atherosclerotic parameters through NF[kappa]B and p38 in vitro. Eur J Clin Invest 2008; 38: 548-554
26. Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008; 294: F1059-F1064
27. Cannon RO III. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809-1819
28. Khan BV, Harrison DG, Olbrych MT, et al. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93: 9114-9119
29. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655
30. Cybulsky MI, Gimbrone MA. Endothelial expression of a mononu-clear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-791
31. Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med 1995; 1: 1002-1004
32. Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endprod-ucts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403
33. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84: 489-497
34. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 3(45 Suppl): S77-S80
35. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-126
36. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 1315-1321
37. Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arte-rioscler Thromb 1994; 14: 1521-1528
38. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319
39. Sattler AM, Schoppet M, Schaefer JR, et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004; 74: 103-106
40. Lacey DL, TimmsE, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-176
41. Hofbauer LC, Schoppet M. Clinical implications of the osteoprote-gerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495
42. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
43. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprote-gerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461-2468
44. Haas M, Leko-Mohr Z, Roschger P, et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 2002; 39: 580-586
45. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194
46. Nitta K, Akiba T, Uchida K, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303-309
47. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-1268
48. Price PA, June HH, Buckley JR, et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 2001; 21: 1610-1616
49. Rashid G, Plotkin E, Klein O, et al. Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C. Am J Physiol Renal Physiol 2009; 296: F60-F66
50. Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvas-cular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 2001; 276: 20659-20672
51. Read MA, Whitley MZ, Gupta S, et al. Tumor necrosis factor alpha-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 1997; 272: 2753-2761
52. Kuldo JM, Westra J, Asgeirsdottir SA, et al. Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}-and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am J Physiol Cell Physiol 2005; 289: C1229-C1239
53. Ingemansson R, Bolys R, Budrikis A, et al. Addition of calcium to Euro-Collins solution is essential for 24-hour preservation of the vas-culature. Ann Thorac Surg 1997; 63: 408-413
54. Ingemansson R, Sjoberg T, Massa G, et al. Long-term preservation of vascular endothelium and smooth muscle. Ann Thorac Surg 1995; 59: 1177-1181
55. Ingemansson R, Sjoberg T, Steen S. Importance of calcium in long-term preservation of the vasculature. Ann Thorac Surg 1996; 61: 1158-1162
56. Stringham JC, Paulsen KL, Southard JH, et al. Prolonging myocardial preservation with a modified University of Wisconsin solution containing 2, 3-butanedione monoxime and calcium. J Thorac Cardiovasc Surg 1994; 107: 764-775
57. Bodelsson M, Arneklo-Nobin B, Tornebrandt K. Cooling augments contractile response to 5-hydroxytryptamine via an endothelium-dependent mechanism. Blood Vessels 1989; 26: 347-359
58. Solberg S, Larsen T, Lindal S, et al. The effects of two different crystalloid cardioplegic solutions on cultured human endothelial cells. J Cardiovasc Surg 1989; 30: 669-674